Review Article

Faktor prognostik pasien Chronic Myeloid Leukemia (CML) yang menggunakan terapi Tyrosine Kinase Inhibitor (TKI) berdasarkan skoring Sokal dan Hasford: sebuah tinjauan sistematik

Roderick Wilson Tendean , Ni Made Renny Anggreni Rena, Tjokorda Gde Dharmayuda

Roderick Wilson Tendean
Mahasiswa Program Studi Sarjana Kedokteran dan Profesi Dokter, Fakultas Kedokteran, Universitas Udayana, Bali, Indonesia. Email: wilsontendeann@gmail.com

Ni Made Renny Anggreni Rena
Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Udayana, RSUP Sanglah, Bali, Indonesia

Tjokorda Gde Dharmayuda
Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Udayana, RSUP Sanglah, Bali, Indonesia
Online First: April 30, 2021 | Cite this Article
Tendean, R., Rena, N., Dharmayuda, T. 2021. Faktor prognostik pasien Chronic Myeloid Leukemia (CML) yang menggunakan terapi Tyrosine Kinase Inhibitor (TKI) berdasarkan skoring Sokal dan Hasford: sebuah tinjauan sistematik. Intisari Sains Medis 12(1): 437-442. DOI:10.15562/ism.v12i1.926


Background: Tyrosine Kinase Inhibitor (TKI) therapy is known to improve overall survival in Chronic Myeloid Leukemia (CML) patients. This research aims to assess the overall survival rate in CML patients using TKI therapy.

Methods: This systematic review is done due to PRISMA statement guidelines. The search was conducted in Pubmed, PubMed Center, and Taylod and Francis database from 2015 to 2018 with inclusion criteria age>18 years, intervention TKI therapy, Sokal and Hasford score, overall survival outcome. The title and abstract of these articles were reviewed for relevance, based on inclusion criteria. This systematic review uses STROBE to evaluate the individual study's quality, which consists of 22 domains.

Results: In the final stage, this systematic review identifies two articles. Overall, the quality of these two articles based on the STROBE checklist is not good. Both articles said that CML patients given TKI therapy with smaller Sokal and Hasford scores would have a higher overall survival rate.

Conclusion: Overall, this systematic review obtained evidence of the high rate of overall survival in CML patients given TKI therapy. One study said that patients with lower Sokal and Hasford scores would have a higher overall survival rate. However, a study related to this is still limited and further research is needed, including larger populations, the evaluation of the mortality rate, and the comparison prognostic factor among TKI therapy.

 

Latar Belakang: Terapi Tyrosine Kinase Inhibitor (TKI) diketahui dapat meningkatkan overall survival pada pasien Chronic Myeloid Leukemia (CML). Tujuan dari penelitian ini adalah untuk menilai tingkat overall survival pada pasien CML yang menggunakan terapi TKI.

Metode: Penulisan tinjauan sistematik ini dilakukan berdasarkan pedoman PRISMA. Pencarian artikel dilakukan pada database Pubmed, PubMed Centre, Taylor and Francis dari tahun 2015 sampai 2018 dengan kriteria inklusi umur >18 tahun, intervensi terapi TKI, skoring Sokal dan Hasford, outcome overall survival. Judul dan abstrak ditinjau berdasarkan relevansi penelitian. Penilaian kualitas studi dilakukan berdasarkan checklist STROBE yang terdiri dari 22 domain.

Hasil: Pada tahap akhir didapatkan studi sebanyak 2 artikel. Secara umum kualitas studi kedua artikel berdasarkan checklist STROBE kurang baik. Kedua studi mendukung bahwa pasien CML yang diberikan terapi TKI dengan skor Sokal maupun Hasford yang semakin kecil akan memiliki tingkat overall survival yang semakin tinggi.

Kesimpulan: Secara umum tinjauan sistematik ini memperoleh bukti mengenai tingginya overall survival pasien CML yang diberikan terapi TKI. Sebagian studi mendukung bahwa pasien dengan skor Sokal dan Hasford yang semakin rendah akan menyebabkan tingginya overall survival. Namun, studi mengenai hal terkait masih terbatas dan dibutuhkan penelitian lebih lanjut yang menyertakan populasi dalam jumlah yang lebih besar, mengevaluasi tingkat mortalitas, dan perbandingan faktor prognostik antar terapi TKI.

 

References

Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87-100.

Szczepa?ski T, van der Velden VH, van Dongen JJ. Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol. 2003;16(4):561-582.

Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. Am Fam Physician. 2014;89(9):731-738.

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87.

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691-709.

Tohami T, Nagler A, Amariglio N. Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia. Isr Med Assoc J. 2012;14(8):501-507.

Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447-1459.

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-2857.

Aijaz J, Junaid N, Asif Naveed M, Maab R. Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores. Cureus. 2020;12(3):e7342.

Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009;15(5):401-405.

Chhikara S, Sazawal S, Singh K, Chaubey R, Pati H, Tyagi S, et al. Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib. South Asian J Cancer. 2018;7(4):258-262.

Payandeh M, Sadeghi M, Sadeghi E. Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran. Asian Pac J Cancer Prev. 2015;16(17):7555-7559.

Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, et al . Nilotinib vs imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours: randomised phase 3 trial results and subgroup analysis of molecular subtypes. Lancet Oncol. 2015;16(5):550-560.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333-40.

Somarnam, Machsoos BD, Hermanto DH. Perbandingan Skor Sokal dan Skor Hasford terhadap Respons Terapi Imatinib Mesylate pada Pasien Leukemia Granulositik Kronis di Rumah Sakit dr. Saiful Anwar Malang. Jurnal Penyakit Dalam Indonesia. 2019;6(4):164-168.

Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, et al. Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients. Cancer Manag Res. 2019;11:1493-1502.

Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs. 2014;74(6):627-43.

Waclaw J, Sacha T, Stoklosa T. Imatinib in the treatment of chronic myeloid leukemia: Current perspectives on optimal dose. Blood and Lymphatic Cancer: Targets and Therapy 2015;5:101-8.


No Supplementary Material available for this article.
Article Views      : 47
PDF Downloads : 24